Kitty
Senior Member (Voting Rights)
..did anyone pay to register/watch then? Just curious.
I usually follow conferences as best I can, but there was no way I could find $50.
..did anyone pay to register/watch then? Just curious.
@hope123 answered on PR. The videos will be made available to watch for registered attendees.They will not be on YouTube.Does anyone know whether the videos will be made available for all to watch?
According to @hope123 post earlier in this thread that is the planNot transparent. Some effort to communicate highlights with the wider ME community should be a basic output.
Finally, we always have a few writers from the ME/CFS community reporting on the meeting. They cover highlights and occasionally interview speakers. Most of these summaries are made available freely after the meeting.
A significant proportion of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and dysautonomia may have potentially treatable underlying autoimmune-associated small-fiber polyneuropathy (aaSFPN), pilot data suggest.
The findings, from a single-site study of 61 patients with ME/CFS, were presented August 21 at the virtual meeting of the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis by Ryan Whelan, BS, a research assistant at Simmaron Research Institute, Incline Village, Nevada.
Recent evidence suggests an autoimmune etiology for some patients with ME/CFS, which is defined as experiencing for a period of at least 6 months profound, unexplained fatigue, postexertional malaise, and unrefreshing sleep, as well as cognitive dysfunction and/or orthostatic intolerance (OI).
OI is part of a spectrum of autonomic dysfunction commonly seen in ME/CFS patients, which may also include postural orthostatic tachycardia (POTS), peripheral temperature dysregulation and light sensitivity, neuropathic pain, and gastrointestinal complaints. Many of these symptoms overlap those reported by patients with aaSFPN, a common but underdiagnosed neurodegenerative disorder characterized by the loss of peripheral autonomic nerve fibers, Whelan explained.
Findings from the current study show that in more than half of ME/CFS patients, levels of at least one autoantibody were elevated. A majority had comorbid POTS or OI, and over a third had biopsy-confirmed aaSFPN.
"Given the overlap of symptoms and common etiological basis, it may be important to identify ME/CFS patients who present with comorbid aaSFPN, as it has been shown that immune modulatory agents, including intravenous gamma globulin [IVIG], reduce the autonomic symptom burden in aaSFPN patients," Whelan said.
He noted that Anne Louise Oaklander, MD, a neurologist at Massachusetts General Hospital, Harvard Medical School, Boston, and colleagues previously linked aaSFPN with fibromyalgia. In addition, they've found a connection between small-fiber dysfunction and postexertional malaise, which is a hallmark ME/CFS symptom.
Asked to comment on Whelan's presentation, IACFSME co-president Lily Chu, MD, told Medscape Medical News that the new findings are "valuable, because ME/CFS has always been looked upon as just subjective symptoms. When people have laboratory abnormalities, it can be due to a bunch of other causes, but...here's pathology, here's a biopsy of actual damage. It's not just a transient finding. You can actually see it.... It's a solid concrete piece of evidence vs something that can fluctuate."
Autoantibodies, Autonomic Dysfunction, and Small-Fiber Polyneuropathy
Whelan and colleagues conducted an extensive analysis of medical records of 364 patients with ME/CFS (72% female) to identify potential aaSFPN comorbidity. Such identifications were made on the basis of progress notes documenting autonomic dysfunction, laboratory results for serum autoantibodies, and questionnaire symptom self-reports.
They identified 61 patients as possibly having comorbid aaSFPN. Of those, 52% tested positive for at least 1 of 4 autoantibodies, including antimuscarinic cholinergic receptor 4 (47%), anti-beta-2 adrenergic (27%), antimuscarinic cholinergic 3 (25%), and anti-beta-1 adrenergic (13%). These autoantibodies were linked to ME/CFS in a recent Swedish cohort study.
Nope. Are they deliberately trying to exclude patients?$40 is (approx) £30 or €34, not sure how many takers there will be for that.
'attendees' had to pay to register in the first place; I'm guessing that maybe there were'nt enough. Maybe if the registration fees hadn't been so high there might have been more.The conferences we normally watch online free probably cover their costs from attendance fees.